Associated Papers
PLCG2 across human disease: genetic variants, signaling mechanisms, and clinical implications.
Jiang P et al.
Journal of Translational Medicine, 2026
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel.
Krigstein M et al.
Annals of Laboratory Medicine, 2025
41277019 (PubMed )
Supplement: ALM3692_Supple1.xlsx › Variant_Calls
Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.
Gruessner C et al.
Leukemia & Lymphoma, 2025
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S et al.
Blood Advances, 2023
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
Smith CIE et al.
Frontiers in Immunology, 2021
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Ondrisova L et al.
Frontiers in Oncology, 2020
33154951 (PubMed )
Supplement: DataSheet_1.pdf
A Germline Mutation in the C2 Domain of PLCγ2 Associated with Gain-of-Function Expands the Phenotype for PLCG2-Related Diseases.
Novice T et al.
Journal of Clinical Immunology, 2020
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
Jones D et al.
Leukemia, 2017
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
Burger JA et al.
Nature Communications, 2016
Select a paper to view details